


PHARMACEUTICAL 2022



PHIBRO ANIMAL HEALTH CORP Rank 82 of 475





PHARMACEUTICAL 2022





PHIBRO ANIMAL HEALTH CORP Rank 82 of 475

The relative strengths and weaknesses of PHIBRO ANIMAL HEALTH CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PHIBRO ANIMAL HEALTH CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 470% points. The greatest weakness of PHIBRO ANIMAL HEALTH CORP is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 290% points.

The company's Economic Capital Ratio, given in the ranking table, is 71%, being 348% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	498,909
Cost of Goods Sold	561,973
Intangible Assets	114,961
Liabilities, Current	164,116
Liabilities, Non-Current	55,970
Other Assets	72,749
Other Compr. Net Income	15,092
Other Expenses	12,083
Other Liabilities	382,710
Other Net Income	-8,400
Property and Equipment	154,706
Research and Development	0
Revenues	833,350
Selling, General and Administrative Expense	196,509

Output Variable	Value in 1000 USD
Assets	841,325
Liabilities	602,796
Expenses	770,565
Stockholders Equity	238,529
Net Income	54,385
Comprehensive Net Income	61,931
Economic Capital Ratio	71%